Slater Vecchio LLP has filed a proposed lawsuit against Janssen Inc. and Teva Branded Pharmaceutical Products R&D, Inc. on behalf of Canadians who were prescribed and ingested Elmiron. The lawsuit alleges that Elmiron causes an undisclosed serious permanent vision loss side effect known as pigmentary maculopathy.
Pigmentary maculopathy is a permanent vision-threatening eye disease characterized by changes to pigment cells in the area of the retina responsible for sharp, detailed central vision.
Individuals with pigmentary maculopathy may experience one or more of the following symptoms:
Pigmentary maculopathy is associated with long-term Elmiron use.
Because the drug companies did not warn of the risk of pigmentary maculopathy on the label for Elmiron, many individuals may have not been diagnosed, or may have been diagnosed with other eye conditions.
The signature changes of pigmentary maculopathy are only visible with the technology used to record images of the interior surface of the eye.
If you are a Canadian who has taken Elmiron, you may have a claim for compensation through the Elmiron class-action lawsuit, whether or not you are currently experiencing symptoms of vision loss.
Doctors are recommending that anyone who has used Elmiron undergo a complete eye exam to see if any damage has been done.
As a prospective claimant, you can submit the form on this page with your information and case details. This will contribute to the case being brought against the manufacturers of this drug.
If you or a loved one have taken Elmiron, contact us now to receive a free review of your case and see if you are eligible for compensation.